Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $3.0 million.

  • Theravance Biopharma's Long-Term Investments changed N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Long-Term Investments is $3.0 million.
  • Over the past 5 years, Theravance Biopharma's Long-Term Investments peaked at $148.2 million during Q2 2022, and registered a low of $2.3 million during Q4 2024.
  • Moreover, its 5-year median value for Long-Term Investments was $19.4 million (2021), whereas its average is $39.9 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first skyrocketed by 42970.2% in 2021, then tumbled by 8004.85% in 2023.
  • Theravance Biopharma's Long-Term Investments (Quarter) stood at $67.5 million in 2021, then surged by 119.51% to $148.2 million in 2022, then tumbled by 87.33% to $18.8 million in 2023, then crashed by 87.79% to $2.3 million in 2024, then skyrocketed by 32.16% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.4 million for Q2 2025, and $2.3 million during Q1 2025.